Assessment of the role of hepatitis C, Helicobacter pylori and autoimmunity in MALT lymphoma of the ocular adnexa in 45 Austrian patients.

INTRODUCTION: A recent series from Italy has suggested a pathogenic link between hepatitis C virus and MALT lymphoma of the ocular adnexa. The hypothesis of our study was to prove this concept in Austrian patients with MALT lymphoma of the ocular adnexa. MATERIALS AND METHODS: A total of 45 patients presenting with MALT lymphoma of the ocular adnexa were assessed for the presence of infection with hepatitis A, B and C. Furthermore, extensive staging to evaluate the extent of disease along with analysis of Helicobacter pylori-infection, the presence or absence of autoimmune diseases (AD) and assessment of MALT-lymphoma specific genetic changes was performed. RESULTS: Only 2/45 (4%) patients were tested positive for hepatitis C, while 10/45 (22%) had an underlying AD and 15/39 (38%) had HP infection. Chromosomal aberrations were detected in 19 (54%) of 35 patients analyzed. Disseminated disease was a significant risk factor for relapse (p=0.014). DISCUSSION: Our series suggests that infection with hepatitis C is not a significant contributor to the pathogenesis of ocular adnexal MALT lymphoma in the Austrian population, while a substantial proportion of these patients suffer from autoimmune conditions.

Serum interleukin-6 levels in patients with gastric MALT lymphoma compared to gastric and pancreatic cancer.

BACKGROUND: Interleukin-6 (IL-6) plays a major role in inflammatory processes and various malignancies. Serum IL-6 levels from patients with gastric MALT lymphoma, gastric cancer and pancreatic cancer was investigated. PATIENTS AND METHODS: The serum 11-6 levels were obtained in a total of 86 patients. A two-tailed Mann-Whitney-test was performed to compare the results. A p-level <0.05 was deemed statistically significant. RESULTS: In lymphoma patients, the mean IL-6 levels were 12.633 pg/ml (SD 10.465). The levels for gastric cancer were 6.324 pg/ml (SD 11.497) and 27.4 pg/ml (SD 86.272) for pancreatic cancer. A comparison between MALT lymphoma and gastric cancer revealed a significant difference (p=0.0030), while no difference was found between MALT lymphoma and pancreatic cancer. The 11-6 levels, however, were higher in pancreatic cancer than gastric cancer (p =0.0040). CONCLUSION: Our results might reflect a greater importance of IL-6 in the development and growth of MALT lymphoma and, possibly, pancreatic cancer than in gastric cancer.

High relapse rate in patients with MALT lymphoma warrants lifelong follow-up.

BACKGROUND: B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) is thought to be an indolent disease, with a good prognosis following various forms of treatment. Little, however, is known about the rate and pattern of relapse following successful treatment. PATIENTS AND METHODS: We have analyzed time to and pattern of relapse in patients with MALT lymphoma, along with investigation of t(11;18)(q21;q21), t(1;14)(p22;q32), and t(14;18)(q32;q21) involving IGH/MALT1, trisomy 3, and trisomy 18. Eighty-six patients achieving complete remission (CR) after initial therapy with sufficient follow-up data were available. Primary site of disease was the stomach (n = 36), salivary gland (n = 19), ocular adnexa/orbit (n = 12), lung (n = 8), thyroid (n = 5), breast (n = 3), liver (n = 2), and skin (n = 1). RESULTS: Thirty-two patients (37%) relapsed between 14 and 307 months (median 47 months) after initial CR. Ten relapses were local, whereas the remaining patients relapsed in a distant organ. Eight of 36 gastric versus 24 of 50 nongastric MALT lymphomas (P = 0.02) relapsed. Five patients had a second recurrence 26 to 56 months after a second CR. Relapse rates were not related to forms of initial treatment. Chromosomal aberrations were detected in 14 of 28 (50%) relapsing patients, and chromosomal alterations were identical at diagnosis and relapse. No significant association of any of the genetic changes investigated with relapse was found. Interestingly, patients with t(11;18)(q21;q21) had a significantly longer median time to relapse (76 months) than patients without this translocation (29 months; P = 0.012). CONCLUSIONS: In view of the late relapses seen in our series, lifelong observation of all patients treated for MALT lymphoma seems to be required.

Transformation of MALT lymphoma to pure plasma cell histology following treatment with the anti-CD20 antibody rituximab.

Mucosa associated lymphoid tissue (MALT) lymphoma is a relatively common lymphoma arising from marginal-zone B-cells which are closely related to plasma cells. As opposed to the large majority of plasma cells, MALT lymphoma cells express CD20, and the anti-CD20 antibody rituximab has been reported as active treatment in patients with MALT lymphoma. We present a patient with MALT lymphoma involving stomach and lung which transformed to a pure plasma cell tumor after therapy with rituximab. This observation again supports the close association between the cell of origin of MALT lymphoma and plasma cells, suggesting that "plasmacytoma of the GI-tract" as anecdotally reported may in fact be a MALT lymphoma with extreme plasmacytic differentiation. In addition, our findings suggest that MALT lymphomas with plasmacytic differentiation might have a different 18F-FDG uptake as compared to classical MALT lymphoma.

Long-term culture-initiating cell assay for mouse cells.

The long-term culture-initiating cell (LTC-IC) assay is a well-established in vitro assay used to enumerate primitive mouse hematopoietic stem cells (HSCs) and relies on the two cardinal functions of HSCs: ability to self-renew and differentiation capacity. LTC-ICs present in minimally processed and purified cell suspensions and cocultured on a supportive feeder layer are detected by their sustained ability to produce hematopoietic progenitors (colony forming cells) after ≥ 4 weeks in culture. Refinements including the use of a defined stromal cell line, and extending the in vitro culture to 6 weeks allow detection of LTC-IC at similar frequencies to transplantable HSCs quantified using in vivo assays.

Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma.

OBJECTIVE: Patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are either not suitable for stem cell transplantation or suffer from relapsed disease after standard second-line chemotherapy face a dismal prognosis. Most of them have a reduced performance status and do not tolerate intensive chemotherapy. METHODS: Twenty patients with relapsed DLBCL were given rituximab 375 mg/m(2) intravenously on day 1, Ara-C 2 x 1,000 mg intravenously on day 2, dexamethasone 40 mg intravenously on days 1-4, and oxaliplatin 130 mg/m(2) intravenously over 2 h on day 3 (R-ADOx). RESULTS: Five patients (25%) achieved a complete remission, 9 (45%) had a partial response , 2 (10%) had stable disease with improvement in performance status, while 4 patients (20%) progressed. The median survival was 11 months (range 1-13). Despite extensive pretreatment, side effects were relatively mild and consisted of thrombocytopenia WHO grade III in 9 (45%) and grade IV in 2 (11%) patients, leukocytopenia WHO grade III in 10 (50%) cases (with infectious episodes in 2 patients), and transient peripheral neuropathy in 9 (45%) patients. CONCLUSION: R-ADOx is well tolerated in heavily pretreated patients with an impaired performance status. In addition, it displays impressive therapeutic activity given the highly unfavorable patient characteristics and should be further investigated for treatment of DLBCL.